The Efficacy of Adjuvant Chemotherapy With Capecitabine (Xeloda) Monotherapy in Patients With Colon Cancer Stage III (Duke C) Considering the Histopathology of the Tumour (AXEL)
N/A
18 Years
N/A
18 Years
N/A
Open (Enrolling)
Both
Colorectal Cancer
Both
Colorectal Cancer
Trial Information
The Efficacy of Adjuvant Chemotherapy With Capecitabine (Xeloda) Monotherapy in Patients With Colon Cancer Stage III (Duke C) Considering the Histopathology of the Tumour (AXEL)
Inclusion Criteria:
- Adult patients, over the age of 18 years
- Presence of colon adenocarcinoma
- Surgical resection for colon cancer stage III (Duke C)
- Prior adjuvant therapy with Xeloda monotherapy
Exclusion Criteria:
- Contraindications for Xeloda
Type of Study:
Observational
Study Design:
Observational Model: Cohort, Time Perspective: Prospective
Outcome Measure:
Disease-free survival
Outcome Time Frame:
3 years
Safety Issue:
No
Principal Investigator
Clinical Trials
Investigator Role:
Study Director
Investigator Affiliation:
Hoffmann-La Roche
Authority:
Romania: National Medicine and Medical Devices Agency (NMMDA)
Study ID:
ML25174
NCT ID:
NCT01276405
Start Date:
March 2010
Completion Date:
October 2014
Related Keywords:
- Colorectal Cancer
- Colorectal Neoplasms
Name | Location |
|---|
